An FDA Category 1 or Category 2 designation describes whether a US compounding pharmacy may legally compound a human medication using that substance
Potential benefits: Research shows that tirzepatide leads to greater weight loss than semaglutidelikely because the two hormone mimickers work together for greater effects
Out of the three options, Thesis has an edge here because it uses some shorter lists of ingredients in doses that are sometimes lower than what human studies confirm to be effective
Competing interests All authors have completed the ICMJE uniform disclosure form at and declare: this study was funded by the Canadian Institutes of Health Research
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid
Most patients lose 15 pounds in 8 to 16 weeks on GLP-1 medications Tirzepatide may produce slightly faster results than Semaglutide Appetite suppression often begins within the first 12 weeks Healthy weight loss averages 1 to 2.5 pounds per week Results depend on dosing, nutrition, activity, and consistency GLP-1 medications such as Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro) are widely used in medical weight loss programs to help reduce appetite and support gradual fat loss